AF
KROS icon

Allworth Financial’s Keros Therapeutics KROS Stock Holding History

Allworth Financial’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Buy
1,358
+1,071
+373% +$11.9K ﹤0.01% 3451
2026
Q1 		$3.17K Sell
287
-321
-53% -$4.96K ﹤0.01% 4183
2025
Q4 		$12.4K Sell
608
-54
-8% -$947 ﹤0.01% 3121
2025
Q3 		$10.5K Buy
662
+31
+5% +$458 ﹤0.01% 3112
2025
Q2 		$8.42K Buy
631
+261
+71% +$3.52K ﹤0.01% 2980
2025
Q1 		$5.34K Buy
+370
New +$4.3K ﹤0.01% 2728

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Allworth Financial's KROS Position: Q2 2026 in Review

Allworth Financial increased its Keros Therapeutics (KROS) stake by 373% in Q2 2026, buying an estimated $11.9K and bringing the position to 1,358 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3451.

Allworth Financial first reported a position in KROS in Q1 2025 and has held it in 6 quarters since. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Allworth Financial held 1,358 shares of Keros Therapeutics worth $14.5K as of Q2 2026.
  • Allworth Financial bought 1,071 Keros Therapeutics shares in Q2 2026, an estimated $11.9K.
  • Keros Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3451 holding.
  • Allworth Financial first reported a position in Keros Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.